Sponsor Check › Person
Named as an officer, director or promoter on SEC Form D filings · NY, CA, WA, British Columbia, Canada (as filed: A1), Quebec, Canada (as filed: A8), MI, CO, MN, OR · Apr 14, 2022 → Oct 16, 2026
Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:16 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET
Peter A. Thompson is listed as an executive officer and director on 76 SEC Form D filings by 29 issuers between Sep 2009 and Oct 2026. Largest by amount reported sold: OrbiMed Private Investments X, LP (New York, NY — pooled investment fund — 2025–2026; $1.92B reported sold to 131 investors), OrbiMed Private Investments IX, LP (New York, NY — pooled investment fund — 2022–2023; $1.85B reported sold to 141 investors), OrbiMed Partners II, L.P. (New York, NY — pooled investment fund — 2022–2026; $1.78B reported sold to 880 investors), OrbiMed RCO V Offshore Feeder, LP (New York, NY — pooled investment fund — 2024–2025; $1.24B reported sold to 31 investors), OrbiMed Royalty & Credit Opportunities V, LP (New York, NY — pooled investment fund — 2024–2025; $1.24B reported sold to 52 investors) and 24 more (all listed below).
What this means That is a lot of deals — 29 separate companies raised money with this person listed as executive officer and director, over about 17 years. Across those companies the filings report $11.2B sold in total.
Listed alongside Carl L. Gordon (25 shared filings), C. Scotland Stevens (24 shared filings), David P. Bonita (24 shared filings), Geoffrey C. Hsu (24 shared filings), Matthew S. Rizzo (24 shared filings) and 172 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Peter. Each name links to their own page.
The issuers belong to 3 sponsor groups: Orbimed (37 issuers, $20.2B reported sold, 2009–2026), Alpine Immune Sciences (2 issuers, $108M reported sold, 2014–2021) and Avalon (15 issuers, $705.3M reported sold, 2010–2025).
What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CO, CT, DC, DE, FINRA, FL, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, WA, WI, WV, WY) — 16 bankruptcy cases matching the name listed in Key records below.
What this means 16 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared the newest 50 of 76 public filings for Peter A. Thompson and found 20 differences, 2 worth asking the sponsor about: Investor count went down between filings; Paid seller listed without a CRD number: UBS Switzerland AG; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.
Community search for Peter A. Thompson has not run yet — it is #5,842 of 59,149 in line; searches run around the clock at the hosts' allowed rate. Searched so far: 669 names.
Community comments are quoted as written by their authors. Sources searched: Bing (site:reddit.com / site:biggerpockets.com) and Reddit's own search, plus DuckDuckGo/Brave/BiggerPockets search when they are answering.
Five things investors ask first. Items still in human review are counted, not shown.
None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:16 AM ET.
State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: 48 regulators (FINRA, NASAA, 37 states) — crawled Oct 24, 2026, 8:48 AM ET
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Peter A. Thompson..
State securities regulators: Securities regulators searched (64,910 actions): FINRA (38,350 actions, 1995–2026), NASAA (31 actions, 2000–2026; listing starts 1997), AK Division of Banking and Securities (273 actions, 1971–2025), AL Securities Commission (880 actions, 2001–2026), AR Securities Department (1,305 actions, 1998–2026), AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), CO Division of Securities (731 actions, 2001–2026; older years from the Internet Archive (snapshot of 2026-05-02)), CT Department of Banking Securities Division (940 actions, 2006–2026; older years from the Internet Archive (snapshot of 2026-04-22)), DC DISB Securities Bureau (25 actions, 2012–2026), DE DOJ Investor Protection Unit (257 actions, 1987–2026), FL Office of Financial Regulation (49 actions, 2018–2026), GA Secretary of State Securities Division (65 actions, 2015–2026; listing starts 2012), HI DCCA Securities Enforcement Branch (26 actions, 2012–2026), ID Department of Finance Securities Bureau (663 actions, 1994–2026), IL Secretary of State Securities Department (4,122 actions, 2003–2023), KS Insurance Department Securities Division (58 actions), KY Department of Financial Institutions (342 actions, 2005–2026), LA Office of Financial Institutions Securities Division (13 actions, 2010–2025; listing starts 2008), MA Secretary of the Commonwealth Securities Division (125 actions, 2012–2025; live site blocks automated access — loaded from the Internet Archive snapshot of 2026-02-04), MD Attorney General Securities Division (1,054 actions, 2004–2026), ME Office of Securities (539 actions, 2000–2026), MI LARA Corporations, Securities & Commercial Licensing Bureau (201 actions), MO Secretary of State Securities Division (919 actions, 1998–2026), MS Secretary of State Securities Division (209 actions, 1995–2026), MT Commissioner of Securities and Insurance (597 actions, 2000–2026), NC Secretary of State Securities Division (265 actions, 2004–2024), ND Securities Department (711 actions, 1990–2026; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2026-01-06), NH Bureau of Securities Regulation (402 actions, 2002–2026), NM Regulation and Licensing Department Securities Division (90 actions, 2010–2025), NV Secretary of State Securities Division (118 actions, 2018–2026), NY Attorney General Investor Protection Bureau (44 actions, 2012–2026), OH Division of Securities (327 actions, 1993–2006), OK Department of Securities (2,531 actions, 1998–2026), OR Division of Financial Regulation (589 actions, 1988–2026), PA Department of Banking and Securities (1,448 actions, 2008–2024; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2024-08-09), RI DBR Securities Division (98 actions, 2005–2025), SC Attorney General Securities Division (540 actions, 2006–2026), SD Division of Insurance – Securities Regulation (106 actions, 2017–2026), TN Department of Commerce and Insurance Securities Division (405 actions, 1992–2026), TX State Securities Board (936 actions, 1999–2026), UT Division of Securities (772 actions, 2000–2026; older years from the Internet Archive (snapshot of 2010-05-27)), VT DFR Securities Division (137 actions, 2010–2026), WA DFI (2,039 actions, 2001–2026), WI DFI Division of Securities (1,072 actions, 1998–2026), WV Securities Commission (State Auditor) (64 actions), WY Secretary of State Compliance Division (6 actions, 2016–2024) — last crawled Oct 24, 2026, 8:48 AM ET. No machine-readable public listing today for IA, IN, MN, NE, NJ, VA (see docs/state-regulators.md).
16 cases: 16 closed (disposition not in docket feed)
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:16 AM ET.
Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.
State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons cover issuers and sponsor groups — see the issuer pages under Deals
20 differences found between the filings for Peter A. Thompson — 2 worth asking about (compared the newest 50 of 76 filings on Oct 24, 2026; older filings not covered)
United States Bankruptcy Court, W.D. Washington docket "Moldt v. US Bank NA" filed Jun 12, 2013, closed Nov 12, 2013. Peter Moldt (listed on the same filings) is listed as Plaintiff ("Moldt"). Our match estimate: 70%.
What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.
United States Bankruptcy Court, C.D. California docket "Stephen D Jones and Zada M Jones" filed May 17, 2000, closed Sep 13, 2000. Basheer Zada (listed on the same filings) is listed as Debtor ("Stephen D Jones and Zada M Jones"). Our match estimate: 63%.
What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.
The Jun 2, 2017 filing reports 32 investors; the Oct 11, 2018 Form D/A reports 31 investors.
What this means Investor counts normally only grow. A smaller number can mean investors left or were refunded, or a count was corrected. Ask the sponsor what happened.
UBS Switzerland AG is listed as receiving sales compensation on 3 filings (Sep 29, 2025 to Oct 16, 2026) with no FINRA CRD number given.
What this means People paid to sell securities normally hold a FINRA registration with a CRD number. Without one we cannot look them up on BrokerCheck. Ask who they are and whether they are registered.
The filing says the first sale was Sep 23, 2025. The Form D was filed Oct 23, 2025 — 30 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 15 days past that.
What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.
The filing says the first sale was May 2, 2025. The Form D was filed May 19, 2025 — 17 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 2 days past that.
What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.
The filing says the first sale was Aug 27, 2019. The Form D was filed Sep 26, 2019 — 30 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 15 days past that.
What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.
No amendment in the last 12 months on an offering that may still be open — Sparrow Pharmaceuticals, Inc. (latest filing Jul 1, 2025) · No amendment in the last 12 months on an offering that may still be open — OrbiMed Royalty & Credit Opportunities V, LP (latest filing May 6, 2025) · No amendment in the last 12 months on an offering that may still be open — OrbiMed RCO V Offshore Feeder, LP (latest filing May 6, 2025) · No amendment in the last 12 months on an offering that may still be open — Sparrow Pharmaceuticals, Inc. (latest filing Apr 12, 2024) · No amendment in the last 12 months on an offering that may still be open — RECODE THERAPEUTICS, INC. (latest filing Sep 28, 2023) · and 15 more
What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.
The Mar 19, 2020 filing lists Peter A. Thompson as executive officer, director; the Oct 6, 2020 Form D lists director.
What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.
Offering amount changed between filings — OrbiMed Private Investments X, LP · Offering amount changed between filings — Alpheus Medical, Inc. · Offering amount changed between filings — RECODE THERAPEUTICS, INC. · Offering amount changed between filings — RECODE THERAPEUTICS, INC. · Offering amount changed between filings — OrbiMed RCO IV Offshore Feeder, LP · and 2 more
What this means Targets change as deals grow or shrink. Ask whether later money has the same terms.
listed as "Peter Thompson" on 21 filings (from Aug 31, 2015), and "Peter A. Thompson" on 31 filings (from Sep 20, 2018).
What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.
Industry group changed between filings — Alpheus Medical, Inc. · Industry group changed between filings — Edgewise Therapeutics, Inc. · Industry group changed between filings — Silverback Therapeutics, Inc. · Industry group changed between filings — ESCAPE Bio, Inc.
What this means Often just a different box ticked; sometimes the deal changed. Ask which business your money is in.
"$25,000,001 - $50,000,000" (Apr 14, 2020); then "Decline to Disclose" (Apr 14, 2021).
What this means This is the size band the issuer picks for itself on the form. A change can mean the business grew or shrank — or that it chose not to say. Ask for current numbers.
The issuer's latest filing says it was formed in 2020. The Aug 31, 2015 filing says the first sale was Aug 19, 2015 — before that year.
What this means A company cannot sell before it exists, so one of the two dates is likely a typo on the form. Ask the sponsor for the formation document.
This page covers filings where the address state is NY or CA or WA or A1 or A8 or MI or CO or MN or OR. A separate record, "Peter Thompson" with address state NJ, is listed on 2 filings — most recently by Gennao Bio, Inc. (Dec 8, 2022). Both records have filings in the same period (Apr 14, 2022 to Dec 8, 2022).
What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.
This page covers filings where the address state is NY or CA or WA or A1 or A8 or MI or CO or MN or OR. A separate record, "Peter A. Thompson" with address state MA, is listed on 1 filing — most recently by Decibel Therapeutics, Inc. (Nov 12, 2020). The two records do not overlap in time: this page runs Apr 14, 2022 to Oct 16, 2026; the other has one filing dated Nov 12, 2020.
What this means Could be the same person who moved, or two people with the same name. We keep them apart until a filing ties them together. Check both pages before you decide.
This page covers filings where the address state is NY or CA or WA or A1 or A8 or MI or CO or MN or OR. A separate record, "Peter Thompson" with address state IL, is listed on 2 filings — most recently by EQDerivatives, Inc. (May 21, 2019). The two records do not overlap in time: this page runs Apr 14, 2022 to Oct 16, 2026; the other runs Jul 2, 2014 to May 21, 2019.
What this means Could be the same person who moved, or two people with the same name. We keep them apart until a filing ties them together. Check both pages before you decide.
This page covers filings where the address state is NY or CA or WA or A1 or A8 or MI or CO or MN or OR. A separate record, "Peter Thompson" with address state NC, is listed on 1 filing — most recently by CARDIOXYL PHARMACEUTICALS INC (Nov 7, 2012). The two records do not overlap in time: this page runs Apr 14, 2022 to Oct 16, 2026; the other has one filing dated Nov 7, 2012.
What this means Could be the same person who moved, or two people with the same name. We keep them apart until a filing ties them together. Check both pages before you decide.
Address moved from Oakdale, MN to Chanhassen, MN — Alpheus Medical, Inc. · Address moved from San Francisco, CA to South San Francisco, CA — ESCAPE Bio, Inc. · Address moved from South San Francisco, CA to San Francisco, CA — ESCAPE Bio, Inc. · Address moved from San Francisco, CA to South San Francisco, CA — ESCAPE Bio, Inc.
What this means Businesses move. If you were told one city and the forms say another, ask which is current.
CA on 13 filings (Aug 31, 2015 to Apr 22, 2026); WA on 6 filings (Sep 20, 2018 to Sep 29, 2021); CO on 2 filings (Sep 26, 2019 to Dec 10, 2020); MN on 4 filings (Dec 23, 2020 to Jul 30, 2026); OR on 3 filings (Jan 13, 2021 to Jul 1, 2025); NY on 24 filings (Apr 14, 2022 to Oct 16, 2026).
What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.
What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. We compared the newest 50 of 76 filings (work cap); older filings are not covered here. As of Oct 24, 2026.
7 of 53 offerings report sales commissions totalling $38,450,693; 2 report finder's fees totalling $306,750; 2 report proceeds to related persons totalling $2,400,000. (includes amounts the issuer reported as estimates)
| Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it | Source |
|---|---|---|---|---|---|
| Oct 16, 2026 D/A OrbiMed Private Investments X, LP File 021-559153 | $0 (est.) | $0 (est.) | $0 (est.) An affiliate of the GPLP will receive a fee for management services. The fee will equal a percentage of aggregate subscriptions of the Issuer's limited partners during the active investment period and a percentage tied to invested capital thereafter. | UBS Switzerland AG no CRD number reported MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED BrokerCheck CRD 7691 ↗ | EDGAR ↗ |
| Jul 30, 2026 D/A Alpheus Medical, Inc. File 021-546462 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jul 10, 2026 D/A OrbiMed Partners II, L.P. File 021-128771 | $30,915,209 (est.) | $0 | $0 The fund charges a management fee that is described in the fund's offering documents. | Far Hills Group, LLC BrokerCheck CRD 000032243 ↗ | EDGAR ↗ |
| Apr 22, 2026 D Terremoto Biosciences, Inc. File 021-581389 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Dec 5, 2025 D/A OrbiMed Genesis Fund, L.P. File 021-355430 | $0 | $0 | $0 The fund charges a management fee that is described in the fund's offering documents. | None listed on this filing | EDGAR ↗ |
| Oct 23, 2025 D RECODE THERAPEUTICS, INC. File 021-561915 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jul 1, 2025 D Sparrow Pharmaceuticals, Inc. File 021-550457 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| May 6, 2025 D/A OrbiMed RCO V Offshore Feeder, LP File 021-529422 | $0 (est.) | $0 (est.) | $0 (est.) An affiliate of the GPLP will receive a fee for management services. The fee will equal a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage of invested capital thereafter. | J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗ | EDGAR ↗ |
| May 6, 2025 D/A OrbiMed Royalty & Credit Opportunities V, LP File 021-529419 | $0 (est.) | $0 (est.) | $0 (est.) An affiliate of the GPLP will receive a fee for management services. The fee will equal a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage of invested capital thereafter. | J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗ | EDGAR ↗ |
| Apr 12, 2024 D Sparrow Pharmaceuticals, Inc. File 021-510516 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Sep 28, 2023 D/A RECODE THERAPEUTICS, INC. File 021-418416 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Apr 28, 2023 D/A OrbiMed Private Investments IX, LP File 021-443751 | $0 | $0 | $0 (est.) An affiliate of the General Partner will receive a fee for management services equal to a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage of invested capital thereafter. | None listed on this filing | EDGAR ↗ |
| Apr 14, 2023 D/A OrbiMed New Horizons Fund, L.P. File 021-364898 | $0 | $0 | $0 The fund charges a management fee that is described in the fund's offering documents. | None listed on this filing | EDGAR ↗ |
| Dec 16, 2022 D/A OrbiMed Royalty & Credit Opportunities IV, LP File 021-443752 | $0 (est.) | $0 (est.) | $0 (est.) An affiliate of the General Partner will receive a fee for management services. The fee will equal a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage of invested capital thereafter. | J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗ | EDGAR ↗ |
| Dec 16, 2022 D/A OrbiMed RCO IV Offshore Feeder, LP File 021-452404 | $0 (est.) | $0 (est.) | $0 (est.) An affiliate of the General Partner will receive a fee for management services. The fee will equal a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage of invested capital thereafter. | J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗ | EDGAR ↗ |
| Nov 9, 2022 D Alpheus Medical, Inc. File 021-464407 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Sep 29, 2021 D ALPINE IMMUNE SCIENCES, INC. File 021-415077 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jan 13, 2021 D Sparrow Pharmaceuticals, Inc. File 021-386188 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Dec 23, 2020 D Alpheus Medical, Inc. File 021-384225 | $301,923 | $0 | $0 | B. Riley Securities, Inc. BrokerCheck CRD 25027 ↗ | EDGAR ↗ |
| Dec 10, 2020 D Edgewise Therapeutics, Inc. File 021-382855 | $0 | $0 | $0 (est.) | None listed on this filing | EDGAR ↗ |
| Oct 6, 2020 D Silverback Therapeutics, Inc. File 021-377225 | $0 | $0 | $0 (est.) | None listed on this filing | EDGAR ↗ |
| Sep 28, 2020 D ESCAPE Bio, Inc. File 021-376482 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Aug 7, 2020 D ALPINE IMMUNE SCIENCES, INC. File 021-372783 | $3,340,002 | $0 | $0 | Cowen and Company BrokerCheck CRD 7616 ↗ Oppenheimer & Co. Inc. BrokerCheck CRD 249 ↗ | EDGAR ↗ |
| Mar 20, 2020 D RECODE THERAPEUTICS, INC. File 021-363315 | $0 | $0 | $400,000 | None listed on this filing | EDGAR ↗ |
| Mar 19, 2020 D Silverback Therapeutics, Inc. File 021-363266 | $0 | $0 | $0 (est.) | None listed on this filing | EDGAR ↗ |
| Sep 26, 2019 D Edgewise Therapeutics, Inc. File 021-349663 | $0 | $0 | $0 (est.) | None listed on this filing | EDGAR ↗ |
| Jul 29, 2019 D ESCAPE Bio, Inc. File 021-345261 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jun 18, 2019 D Cleave Biosciences, Inc. File 021-342143 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jan 30, 2019 D ALPINE IMMUNE SCIENCES, INC. File 021-331755 | $907,499 | $75,000 | $0 | Piper Jaffray & Co. BrokerCheck CRD 665 ↗ | EDGAR ↗ |
| Oct 11, 2018 D/A ESCAPE Bio, Inc. File 021-246718 | $0 | $0 | $0 (est.) | None listed on this filing | EDGAR ↗ |
| Sep 20, 2018 D Silverback Therapeutics, Inc. File 021-321856 | $0 | $0 | $0 (est.) | None listed on this filing | EDGAR ↗ |
| Sep 5, 2018 D Principia Biopharma Inc. File 021-320699 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Apr 27, 2018 D Synthorx, Inc. File 021-311122 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Mar 14, 2018 D Prevail Therapeutics Inc. File 021-307751 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jan 8, 2018 D Silverback Therapeutics, Inc. File 021-302681 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jul 24, 2017 D Alpine Immune Sciences, Inc. File 021-291377 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Feb 6, 2017 D/A Silverback Therapeutics, Inc. File 021-261100 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 30, 2016 D Silverback Therapeutics, Inc. File 021-275309 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Aug 17, 2016 D Cleave Biosciences, Inc. File 021-269114 | $0 | $0 | $0 The Issuer will use proceeds for general working capital purposes which includes payments to its executive officers and other employees in the ordinary course of business. | None listed on this filing | EDGAR ↗ |
| Jun 21, 2016 D Alpine Immune Sciences, Inc. File 021-265425 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Apr 12, 2016 D Silverback Therapeutics, Inc. File 021-261099 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Sep 25, 2015 D Corvus Pharmaceuticals, Inc. File 021-248244 | $0 | $0 | $0 | N/A no CRD number reported | EDGAR ↗ |
| Aug 4, 2015 D Principia Biopharma Inc. File 021-245075 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Dec 8, 2014 D Corvus Pharmaceuticals, Inc. File 021-229629 | $0 | $0 | $0 | N/A no CRD number reported | EDGAR ↗ |
| Oct 2, 2014 D Adaptimmune Ltd File 021-225667 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| May 1, 2014 D ProNAi Therapeutics Inc File 021-216611 | $0 | $0 | $0 (est.) | None listed on this filing | EDGAR ↗ |
| Oct 15, 2013 D RESPONSE BIOMEDICAL CORP File 021-204485 | $74,295 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 21, 2012 D MethylGene Inc. File 021-187365 | $1,000,000 | $0 | $0 | MTS SECURITIES, LLC BrokerCheck CRD 104059 ↗ Jefferies & Company, Inc. BrokerCheck CRD 2347 ↗ | EDGAR ↗ |
| Nov 16, 2012 D/A MethylGene Inc. File 021-158022 | $1,911,765 | $0 | $0 | MTS SECURITIES, LLC BrokerCheck CRD 104059 ↗ | EDGAR ↗ |
| Aug 1, 2012 D Ocunexus Therapeutics, Inc. File 021-182089 | $0 | $0 | $0 (est.) | None listed on this filing | EDGAR ↗ |
| May 13, 2011 D Ocunexus Therapeutics, Inc. File 021-159761 | $0 | $0 | $2,000,000 (est.) | None listed on this filing | EDGAR ↗ |
| Aug 12, 2010 D RESPONSE BIOMEDICAL CORP File 021-146354 | $0 | $231,750 | $0 | Trout Capital LLC BrokerCheck CRD 131489 ↗ | EDGAR ↗ |
| Sep 4, 2009 D Trubion Pharmaceuticals, Inc File 021-67751 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
Every issuer that named Peter A. Thompson on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.
Raised $1.92B from 131 investors (100% of the $1.92B target) as of the latest filing. Peter is listed as executive officer on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $60.5M from 23 investors (90% of the $67M target) as of the latest filing. Peter is listed as director on 4 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $1.78B from 880 investors as of the latest filing. Peter is listed as executive officer on 5 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $40.7M from 14 investors (38% of the $108.6M target) as of the latest filing. Peter is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $353.3M from 107 investors as of the latest filing. Peter is listed as executive officer on 4 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $259.8M from 28 investors (100% of the $29.4M target) as of the latest filing. Peter is listed as director on 6 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $61.8M from 17 investors (51% of the $121.4M target) as of the latest filing. Peter is listed as director on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $1.24B from 52 investors (71% of the $1.75B target) as of the latest filing. Peter is listed as executive officer on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $1.24B from 31 investors (71% of the $1.75B target) as of the latest filing. Peter is listed as executive officer on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $1.85B from 141 investors (97% of the $1.9B target) as of the latest filing. Peter is listed as executive officer on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $61.6M from 55 investors as of the latest filing. Peter is listed as executive officer on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $344.5M from 18 investors (69% of the $500M target) as of the latest filing. Peter is listed as executive officer on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $1.15B from 113 investors (66% of the $1.75B target) as of the latest filing. Peter is listed as executive officer on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $91M from 25 investors (100% of the $91M target) as of the latest filing. Peter is listed as director on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $95M from 21 investors (100% of the $95M target) as of the latest filing. Peter is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $85M from 31 investors (100% of the $85M target) as of the latest filing. Peter is listed as director, executive officer on 8 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $73M from 32 investors (100% of the $73M target) as of the latest filing. Peter is listed as director on 5 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $26M from 13 investors (100% of the $20.8M target) as of the latest filing. Peter is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $50M from 24 investors (100% of the $50M target) as of the latest filing. Peter is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $26.5M from 10 investors (42% of the $63.7M target) as of the latest filing. Peter is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $57M from 15 investors (88% of the $65M target) as of the latest filing. Peter is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $17M from 3 investors (100% of the $17M target) as of the latest filing. Peter is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $75M from 33 investors (100% of the $75M target) as of the latest filing. Peter is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $103.8M from 22 investors (100% of the $103.8M target) as of the latest filing. Peter is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $59.5M from 57 investors (100% of the $59.5M target) as of the latest filing. Peter is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $7.72M from 12 investors (100% of the $4M target) as of the latest filing. Peter is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(c) (171 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $35.6M from 20 investors (100% of the $35.5M target) as of the latest filing. Peter is listed as director on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $19.4M from 4 investors (100% of the $19.4M target) as of the latest filing. Peter is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $10M from 1 investor (100% of the $10M target) as of the latest filing. Peter is listed as executive officer, director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.
Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.
OrbiMed Advisors LLC is on 22 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Peter A. Thompson. Their page shows their other deals.
Listed on the same filings as Peter A. Thompson. Their page shows their other deals.
Listed on the same filings as Peter A. Thompson. Their page shows their other deals.
Listed on the same filings as Peter A. Thompson. Their page shows their other deals.
Listed on the same filings as Peter A. Thompson. Their page shows their other deals.
Listed on the same filings as Peter A. Thompson. Their page shows their other deals.
Carl L. Gordon is on 62 issuers in total — a repeat sponsor. Their page lists every one.
Geoffrey C. Hsu is on 18 issuers in total — a repeat sponsor. Their page lists every one.
W. Carter Neild is on 25 issuers in total — a repeat sponsor. Their page lists every one.
Matthew S. Rizzo is on 9 issuers in total — a repeat sponsor. Their page lists every one.
C. Scotland Stevens is on 12 issuers in total — a repeat sponsor. Their page lists every one.
David P. Bonita is on 28 issuers in total — a repeat sponsor. Their page lists every one.
Sven H. Borho is on 27 issuers in total — a repeat sponsor. Their page lists every one.
Jonathan Root is on 19 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Peter A. Thompson. Their page shows their other deals.
Listed on the same filings as Peter A. Thompson. Their page shows their other deals.
Listed on the same filings as Peter A. Thompson. Their page shows their other deals.
James Topper is on 24 issuers in total — a repeat sponsor. Their page lists every one.
Peter Moldt is on 11 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Peter A. Thompson. Their page shows their other deals.
Alan Colowick is on 10 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Peter A. Thompson. Their page shows their other deals.
Asish Xavier is on 22 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Peter A. Thompson. Their page shows their other deals.
Listed on the same filings as Peter A. Thompson. Their page shows their other deals.
Listed on the same filings as Peter A. Thompson. Their page shows their other deals.
Listed on the same filings as Peter A. Thompson. Their page shows their other deals.
Listed on the same filings as Peter A. Thompson. Their page shows their other deals.
Lewis J. Shuster is on 7 issuers in total — a repeat sponsor. Their page lists every one.
Oleg Nodelman is on 12 issuers in total — a repeat sponsor. Their page lists every one.
Laura Shawver is on 7 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Peter A. Thompson. Their page shows their other deals.
Listed on the same filings as Peter A. Thompson. Their page shows their other deals.
Listed on the same filings as Peter A. Thompson. Their page shows their other deals.
Listed on the same filings as Peter A. Thompson. Their page shows their other deals.
Listed on the same filings as Peter A. Thompson. Their page shows their other deals.
Listed on the same filings as Peter A. Thompson. Their page shows their other deals.
One team, 37 deal companies. Peter A. Thompson is listed on 9 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Peter A. Thompson.
One team, 2 deal companies. Peter A. Thompson is listed on 2 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Peter A. Thompson.
One team, 15 deal companies. Peter A. Thompson is listed on 1 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Peter A. Thompson.
A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.
Individuals are not matched to business registrations — registries list companies, and a name alone is not enough to tie a person to one. Officers and managers appear by name inside each matched company's record on the issuer pages. Registries searched: AL (Alabama Secretary of State — Business Entity Records (arc-sos.state.al.us), searched by issuer name, data as of Oct 24, 2026); CO (Colorado Secretary of State — Business Entities in Colorado (data.colorado.gov), data as of Oct 23, 2026); CT (Connecticut Secretary of the State — Business Registry (data.ct.gov), data as of Oct 24, 2026); FL (Florida Department of State, Division of Corporations — quarterly corporate data file (Sunbiz), data as of Oct 7, 2026); KY (Kentucky Secretary of State — Business Entity Search (sosbes.sos.ky.gov), searched by issuer name, data as of Oct 24, 2026); NY (New York Department of State — Corporations and Other Entities (data.ny.gov: All Filings + Active Corporations), data as of Oct 20, 2026); OR (Oregon Secretary of State — Active Businesses, All (data.oregon.gov), data as of Oct 20, 2026); PA (Pennsylvania Department of State — Registered Businesses, Current (data.pa.gov), data as of Oct 6, 2026); TX (Texas Comptroller — Active Franchise Taxpayers incl. Secretary of State file data (data.texas.gov), data as of Oct 24, 2026). Registries of other states have not been searched: many publish no bulk file and require a CAPTCHA or bot challenge on their search page, which we do not bypass (Delaware, for example, offers no public bulk file).
A person is never an adviser firm. 9 of the 29 issuers this person is listed on match a Form ADV adviser (searched 24,962 advisers as of Oct 2, 2026): OrbiMed Private Investments X, LP, OrbiMed Partners II, L.P., OrbiMed Genesis Fund, L.P., OrbiMed RCO V Offshore Feeder, LP, OrbiMed Royalty & Credit Opportunities V, LP, OrbiMed Private Investments IX, LP, OrbiMed New Horizons Fund, L.P., OrbiMed Royalty & Credit Opportunities IV, LP, OrbiMed RCO IV Offshore Feeder, LP.
Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.
Property records are matched to companies only, never to individuals, so none are matched to Peter A. Thompson by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 29 issuers this person is listed on — 1 issuer has property records: RECODE THERAPEUTICS, INC. (1).
Websites and social links of the issuers Peter A. Thompson is listed on: none on file. No website or social profile named in OrbiMed Partners II, L.P.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #18,193 of 374,652 in line (1,386 issuers searched so far). One-tap searches: Look further ↓
One-tap searches on sites we do not index ourselves, with the name pre-filled (New York, NY). Each opens in a new tab; what you find there is not verified by PartnerFacts.
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Peter A. Thompson appears on a new Form D, or when a court case or SEC action is matched to them. See plans →